Logo
Login
$ANIP
$72.60 -$0.01 (0.01%) Close

Company Executives

$ANIP Management Team

Ms. Lisa Wilson

Investor Relations

Age -
Compensation -
Sex Female

Mr. Patrick Walsh

Independent Chairman of the Board

Age 64
Compensation $373.9K USD
Sex Male

Mr. Thomas Rowland

Senior Vice President

Head of Established Brands

Age 59
Compensation -
Sex Male

Mr. Nikhil Lalwani

President

Chief Executive Officer

Director

Age 47
Compensation $8.859M USD
Sex Male

Mr. Stephen Carey

Chief Financial Officer

Senior Vice President - Finance

Age 54
Compensation $2.850M USD
Sex Male

Ms. Krista Davis

Chief Human Resources Officer

Senior Vice President

Age 52
Compensation -
Sex Female

Ms. Meredith Cook

Senior Vice President

General Counsel

Corporate Secretary

Age 51
Compensation $2.022M USD
Sex Female

Mr. Chad Gassert

Senior Vice President - Corporate Development and Strategy

Age 49
Compensation $1.896M USD
Sex Male

Mr. Ori Gutwerg

Senior Vice President - Generics

Age 51
Compensation $2.108M USD
Sex Male

Mr. Christopher Mutz

Senior Vice President

Head of Rare Diseases

Age 54
Compensation $2.418M USD
Sex Male

Mr. Muthusamy Shanmugam

Director

Head of Research and Development

Chief Operating Officer - Novitium Operations

Age 57
Compensation -
Sex Male

Board of Directors

From the proxy statement filed Apr 9, 2026
Directors
8
serving now
Independent
6 of 6
stated in the proxy; 2 not stated
Average tenure
5.4 years
from year joined
CEO also chairs the board
No
Thomas J. Haughey
Director Age On board Independent Committees Other public boards 2025 pay Source
Thomas J. Haughey
Board chair
 62 2018
8 years
 Independent
Audit and Finance
None stated $343,089
Nikhil Lalwani
CEO
 48 2020
6 years
 Not stated None stated None stated Paid as CEO
Matthew J. Leonard
60 2023
3 years
 Independent
Audit and Finance
None stated $327,573
Antonio R. Pera
68 2020
6 years
 Independent
Compensation · Chair
None stated $327,573
Muthusamy Shanmugam
Executive officer
 58 2021
5 years
 Not stated None stated None stated Not stated
Renee P. Tannenbaum
74 2022
4 years
 Independent
Compensation Nominating and Corporate Governance · Chair
Cardiff Oncology, Inc. $332,573
Jeanne A. Thoma
66 2020
6 years
 Independent
Audit and Finance · Chair Compensation
Nanoform Finland Oyj $331,330
Patrick D. Walsh Leaving at the meeting
Not stated Not stated Independent None stated None stated $345,800

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

No related-party transactions disclosed

The proxy filed Apr 9, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans